Mineralocorticoid receptor antagonists and endothelial function

Current Opinion in Investigational Drugs

Volumn 9, Issue 9, 2008, Pages 963-969

  Maron, B A ^a   Leopold, J A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aldosterone; Congestive heart failure; Endothelial function; Eplerenone; Hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HEPARIN; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; MENSTRUAL IRREGULARITY; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ENDOCRINE SYSTEM DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERALDOSTERONISM; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 50249143541     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens (1997) 10(12 Pt 1):1326-1334.
2. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J (1998) 19(9):1371-1376.
3. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 101(6):594-597. •• This study was the first to demonstrate that, in patients with congestive heart failure, impaired endothelium-dependent vascular reactivity was improved by treatment with spironolactone.
4. Weber KT: Aldosterone in congestive heart failure. N Engl J Med (2001) 345(23):1689-1697. • This comprehensive review details the cardiovascular effects of hyperaldosteronism in the clinical setting of congestive heart failure.
5. Booth RE, Johnson JP, Stockand JD: Aldosterone. Adv Physiol Educ (2002) 26(1-4):8-20.
6. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 113(9):1213-1225.
7. Tokmakova M, Solomon SD: Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: Lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol (2006) 21(4):268-272.
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 348(5):383-393.
9. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol (2007) 3(9):486-492. • A comprehensive study of the incidence of aldosterone breakthrough and the clinical implications for patients treated with ACE inhibitors and ARBs.
10. Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) (2002) 103(4):425-431. •• This was the first study to demonstrate that aldosterone induces endothelial dysfunction by decreasing bioavailable nitric oxide when infused into healthy volunteers.
11. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE: Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension (2003) 42(2):156-160.
12. Nietlispach F, Julius B, Schindler R, Bernheim A, Binkert C, Kiowski W, Brunner-La Rocca HP: Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension (2007) 50(1):82-88.
13. Oberleithner H, Riethmuller C, Ludwig T, Hausberg M, Schillers H: Aldosterone remodels human endothelium. Acta Physiol (Oxf) (2006) 187(1-2):305-312.
14. Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M: Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA (2007) 104(41):16281- 16286.
15. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y: Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology (2008) 149(3):1009-1014.
16. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 13(2):189-197. • This study demonstrated that aldosterone induced endothelial dysfunction by increasing reactive oxygen species production, as well as decreasing antioxidant enzyme capacity. In vivo, this was associated with impaired endothelium-dependent vascular reactivity.
17. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M: Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension (2006) 48(1):165-171.
18. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension (2003) 42(1):49-55.
19. Cachofeiro V, Miana M, de Las Heras N, Martin-Fernandez B, Ballesteros S, Fernandez-Tresguerres J, Lahera V: Aldosterone and the vascular system. J Steroid Biochem Mol Biol (2008).
20. Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev (2005) 10(1):23-29.
21. Greenblatt DJ, Koch-Weser J: Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. J Am Med Assoc (1973) 225(1):40-43.
22. Overdiek HW, Merkus FW: Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther (1986) 40(5):531-536.
23. Nolan PE Jr: Integrating traditional and emerging treatment options in heart failure. Am J Health Syst Pharm (2004) 61 (Suppl 2):S14-S22.
24. Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E: Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology (1992) 102(5):1680- 1685.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 341(10):709-717. •• A landmark clinical trial that demonstrated a 30% decrease in mortality in patients with congestive heart failure and decreased left ventricular function when treated with spironolactone.
26. Struthers AD: Impact of aldosterone on vascular pathophysiology. Congest Heart Fail (2002) 8(1):18-22.
27. Hadi HA, Carr CS, Al Suwaidi J: Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag (2005) 1(3):183-198.
28. Macdonald JE, Kennedy N, Struthers AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90(7):765-770.
29. Abiose AK, Mansoor GA, Barry M, Soucier R, Nair CK, Hager D: Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am J Cardiol (2004) 93(12):1564-1566.
30. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA: Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation (2004) 109(23):2857-2861. •• This study revealed that hyperaldosteronism associated with hypertension decreased vascular endothelial function, an effect that was abrogated by spironolactone.
31. Davies JI, Band M, Morris A, Struthers AD: Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia (2004) 47(10):1687-1694. • This study of patients with diabetes mellitus and impaired endothelial function revealed that spironolactone worsened endothelium-dependent vasodilation, providing evidence that not all patient populations benefit from MR antagonism.
32. Shah NC, Pringle SD, Donnan PT, Struthers AD: Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens (2007) 25(11):2345-2351.
33. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care (2005) 28(9):2106-2112.
34. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J (2000) 321(7258):405-412.
35. Brown NJ: Eplerenone: Cardiovascular protection. Circulation (2003) 107(19):2512-2518.
36. 14C]eplerenone after oral administration to humans. Drug Metab Dispos (2003) 31(11):1448-1455.
37. Inspra (eplerenone tablets): Full prescribing information. Pfizer Inc, New York, NY, USA (2008). http://media.pfizer.com/files/products/ uspi_inspra.pdf
38. Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L: Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos (2002) 30(12):1344-1351.
39. Marcy TR, Ripley TL: Aldosterone antagonists in the treatment of heart failure. Am J Health Syst Pharm (2006) 63(1):49-58.
40. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J et al: Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther (1987) 240(2):650-656.
41. McManus F, McInnes GT, Connell JM: Drug insight: Eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab (2008) 4(1):44-52.
42. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 348(14):1309-1321. •• A large-scale, randomized, clinical trial that demonstrated that the early administration of eplerenone to patients with acute myocardial infarction and left ventricular dysfunction decreased mortality.
43. Struthers AD: Aldosterone blockade in cardiovascular disease. Heart (2004) 90(10):1229-1234.
44. Sanz-Rosa D, Oubiña MP, Cediel E, de las Heras N, Aragoncillo P, Balfagon G, Cachofeiro V, Lahera V: Eplerenone reduces oxidative stress and enhances eNOS in SHR: Vascular functional and structural consequences. Antioxid Redox Signal (2005) 7(9-10):1294-1301.
45. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation (2002) 105(18):2212-2216.
46. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension (2005) 46(5):1135-1139.
47. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK: Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab (2007) 92(7):2552-2558. •• In contrast to what was observed with spironolactone, this study revealed that eplerenone did not decrease endothelial function in patients with diabetes, and improved myocardial perfusion reserve.
48. Goldfien A: The gonadal hormones and inhibitors. In: Basic and Clinical Pharmacology. Katzung B (Ed), McGraw-Hill, New York, NY, USA (1998):653-683.
49. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol (1987) 60(10):820-825.